Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In a randomized Phase 2 trial of 96 patients with locally advanced squamous cell carcinoma of the head and neck, xevinapant (Debio 1143) plus standard…
Merck KGaA has agreed to pay Debiopharm approximately $225 million (EUR 188 million) upfront and up to $850 million (EUR 710 million) in milestones for global…
Following the negative Phase 3 TrilynX readout in October 2023 and additional analyses, Merck KGaA announced that it has discontinued the development of…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Merck KGaA secured worldwide in-licensing rights to xevinapant from Debiopharm, a first-in-class oral IAP antagonist in Phase III for high-risk LA SCCHN. Debiopharm received EUR 188M (~$225M) upfront plus up to EUR 710M (~$850M) in regulatory and commercial milestones, plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / Debiopharm (this deal) | 2021 | $1.1B | — |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Threshold Pharmaceuticals, Inc. | 2012 | $550M | — |
← Browse all deals · How we score deals
More: 2021 deals · Merck KGaA deals · Oncology deals